Navigation Links
NanoInterventions Launches New, Rapid Testing System for Coronary Stents
Date:6/17/2008

Two Minnesota bio-science companies, The Integra Group of Brooklyn Park and Nanocopoeia of St. Paul, team in a global effort to speed the path to

market for advances in cardiovascular medicine

BROOKLYN PARK, Minn. and SAN DIEGO, June 17 /PRNewswire/ -- Coinciding with the BIO International Convention held in San Diego CA, NanoInterventions introduces the "Mouse Stent Model" for rapid screening of new coronary stent therapeutics. The model, complete with a mini-stent of spectacularly small size and its ability to replicate the human diseased vessel, represents a new starting point in the development of next-generation drug-eluting coronary stents. The company, NanoInterventions, emerged from the strategic global partnership of Minnesota-based The Integra Group of Brooklyn Park and Nanocopoeia of St. Paul, along with Stentome, with operations in Palo Alto CA, Galway, Ireland and Oxford, UK, and the University of Western Ontario, in London ON.

The Twin Cities is already home to two of the three largest stent manufacturers and one of the largest clusters of medical device companies in the world. With its local headquarters and base of operations, combined with its global network of partners, NanoInterventions is ideally positioned to speed the development of these life saving devices. The new starting point for testing new stent-delivered therapies brings the customer many novel benefits, including: establishing efficacy much earlier in the process, speeding development-the experimental model requires 28 day cycle versus a 180 day average cycle-and exploring molecular mechanisms of action in the setting of a stented, diseased vessel. NanoInterventions' managing partner, Robert A. Hoerr, MD, PhD, who is Nanocopoeia's CEO, stated, "Our position within the heart of Minnesota's world-class medical device community enabled us to build strategic relationships with the talent and technology needed to launch this new development pathway for
'/>"/>

SOURCE NanoInterventions
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
2. Novozymes Launches Enzyme to Reduce Acrylamide in Food
3. Enova Medical Launches Exos Corporation
4. Elekta Launches New Linear Accelerator at 2007 ESTRO to Expand Cancer Treatment Availability
5. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
6. ThirdBiotech Networking Group Launches
7. BioReliance Launches Next-Generation Genotoxicity Screening Service
8. Midwest Research Institute Launches Center for Biological Safety and Security (CBS2)
9. BioReliance Corporation Launches iNet(TM) for Online Results Tracking of Biological Safety Tests
10. Kingfisher Healthcare Launches Breakthrough Product in Europe
11. Spectral partner launches EAA(TM) Rapid Sepsis Diagnostic in Germany
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... Oral Amphotericin B program.  The company recently announced ... work involving samples from HIV/AIDS patients exposed to ... clinical studies and regulatory filings to move forward ... approximately $700,000 of funding and technological advice from ...
(Date:10/20/2014)... NEW YORK , Oct. 20, 2014 /PRNewswire/ ... of their experimental ZMapp™ antibody therapeutic to fight ... of how difficult and time-consuming the production of ... healthcare market research publisher said that while some ... cycle of this compound, those with industry knowledge ...
(Date:10/20/2014)... Md. , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... Zola P. Horovitz , Ph.D., from its board of directors ... board in August 2003, and served as its chairman from ... served on the Nominating and Corporate Governance and Audit Committees ... for more than a decade of dedicated service to GenVec, ...
(Date:10/19/2014)... The Latin American hardware encryption display market ... with analysis and forecast of revenue. This market was ... to reach $2,366.8 million by 2018, at a CAGR ... the TOC of the Latin American hardware encryption market ... provided. It also provides a glimpse of the segmentation ...
Breaking Biology Technology:iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Zola P. Horovitz To Retire From GenVec Board 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3
... HEIDELBERG, Germany, September 16 , ... Approach Identifies new,Potential Drug Targets in Wnt Pathway , ... inhibition,stabilizes axin and antagonizes Wnt signalling"** is now available online ... Cellzome,s quantitative chemical proteomics,platform was used to identify a small ...
... , , SAN ... College), a private medical school with more than 1,100 physicians, in ... solution to track, manage and report adverse and near-miss events, as ... Manager (EM) and Claims Manager (CM) modules, part of the SRM ...
... , SAN DIEGO, Sept. 16 Hollis-Eden Pharmaceuticals, ... of a new class of small molecule compounds based on endogenous ... The NASDAQ Stock Market on September 15, 2009. , , ... with Nasdaq Marketplace Rule 4450(a)(5) (the "Minimum Bid Price Rule") because ...
Cached Biology Technology:Cellzome Technology Used to Unravel Novel Regulatory Mechanism in Cancer Signaling Pathway 2The Medical College of Wisconsin Adopts Quantros Event Manager(TM) and Claims Manager(TM) for Comprehensive Malpractice Litigation Management 2Hollis-Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price 2Hollis-Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price 3
(Date:10/19/2014)... over the last 30 years contributed only marginally ... that time, according to a new study published ... "Energy access is fundamental to development: it brings ... communication, and health," says IIASA researcher Shonali Pachauri, ... access is widely agreed to be an important ...
(Date:10/18/2014)... patients referred for evaluation of suspected genetic conditions, ... 25 percent, including detection of a number of ... disease, according to a study appearing in ... coincide with the American Society of Human Genetics ... or coding regions of thousands of genes simultaneously ...
(Date:10/17/2014)... Accurate knowledge regarding Ebola is critical and pertinent for ... hazardous global outbreak and epidemic. The Journal, Disaster ... special issue, Ebola Virus and Public Health, to surround ... in this critical societal moment. , On October ... for Clinicians . The primer was prepared by Dr. ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Whole-exome sequencing shows potential as diagnostic tool 2
... in Uganda who self-paid for their antiretroviral medications experienced ... or supply logistical disruptions. These treatment interruptions led ... patients. , These findings by a team led by ... Kampala, and UCSF are reported in the April 22, ...
... pediatric specialists at Baylor College of Medicine have discovered a ... that allows drugs to enter cancer cells. , The research ... and Biomolecular Chemistry. , All living cells defend themselves ... form a protective cocoon around the cell's inner machinery and ...
... cells to turnover their contents, something that they do ... and radiation, but it is not known if this ... survive the anti-cancer therapy. However, in a study using ... the University of Pennsylvania have now shown that autophagy ...
Cached Biology News:Resistance to anti-HIV drugs in Uganda developed due to drug supply problems 2Buckyballs used as 'passkey' into cancer cells 2
The filter 605DF50 for the Molecular Imager FX is a band pass filter for ethidium bromide, SYPRO Red, SYPRO Ruby, Alexa Fluor 532 and 546, and Cy3 dyes when using the 635 nm laser....
The filter 530DF28 for the Molecular Imager FX is a band pass filter for ECL Plus, AttoPhos, SYBR Green, Alexa Fluor 488, FITC, Cy2, and Pro-Q Emerald dyes....
... Sytem is a highly advanced digital ... digital imaging and automation technology that ... analysis, archving/retrieval and colored professional reporting. ... imaging system that aids in performing ...
... single-step staining method for labeling DNA breaks ... The kit contains all the key reagents ... positive and negative control cells for assessing ... for processing individual steps in the assay; ...
Biology Products: